Clinical trial
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in…
NCT00193596 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193596 |
|---|---|
| Title | Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site |
| Official title | A Randomized, Phase III Comparison of Gemcitabine/Irinotecan Followed by IRESSA Versus Paclitaxel/Carboplatin/Etoposide Followed by IRESSA in the First-Line Treatment of Patients With Carcinoma of Unknown Primary Site |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | AstraZeneca Industry Pharmacia and Upjohn Eli Lilly and Company |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neoplasms, Unknown Primary |
| Intervention type | Drug |
| Interventions | Etoposide, Gemcitabine, Irinotecan, Paclitaxel, Carboplatin |
| Enrollment | 198 |
| Start date | Sep 1, 2003 |
| Primary completion | Sep 1, 2008 |
| Completion | Jun 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | May 3, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: